2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac death
2020
Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention 2020, 15: 1190-1198. PMID: 31475907, DOI: 10.4244/eij-d-19-00552.Peer-Reviewed Original ResearchConceptsDevice success rateDrug-eluting stentsPercutaneous coronary intervention trialsCoronary intervention trialsDevice successIntervention trialsClinical trialsSuccess rateSymptomatic coronary artery diseasePercutaneous coronary interventionAdverse clinical eventsCoronary artery diseasePercutaneous Cardiovascular InterventionsDifferent trialsRevascularisation proceduresCoronary interventionAngiographic outcomesArtery diseaseClinical eventsComparative trialsEndpoint definitionsDrug AdministrationCardiovascular interventionsPerformance endpointEuropean Association
2015
Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial
Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, Stone GW. Prognostic utility of myocardial blush grade after PCI in patients with NSTE‐ACS: Analysis from the ACUITY trial. Catheterization And Cardiovascular Interventions 2015, 88: 215-224. PMID: 25641255, DOI: 10.1002/ccd.25865.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary CirculationCoronary VesselsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial Perfusion ImagingNon-ST Elevated Myocardial InfarctionOdds RatioPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsRisk AssessmentRisk FactorsTreatment OutcomeConceptsMyocardial blush gradePercutaneous coronary interventionST-segment elevation myocardial infarctionNSTE-ACS patientsComposite ischemiaMBG 0/1Non-ST segment elevation acute coronary syndromesSegment elevation acute coronary syndromesElevation acute coronary syndromeFinal myocardial blush gradeIndependent angiographic core laboratoryNet adverse clinical eventsNon-CABG major bleedingNormal epicardial flowOutcomes of patientsTIMI 3 flowAcute coronary syndromeIschemia-driven revascularizationAdverse clinical eventsElevation myocardial infarctionNormal myocardial perfusionAngiographic core laboratoryHigh rateACUITY trialMajor bleeding
2013
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stents
2012
Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial)
Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, Lansky AJ, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Stone GW. Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). The American Journal Of Cardiology 2012, 111: 643-648. PMID: 23261001, DOI: 10.1016/j.amjcard.2012.11.011.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSignificant coronary artery diseaseCoronary artery diseaseElevation myocardial infarctionArtery diseaseMyocardial infarctionGreater left ventricular ejection fractionMajor adverse cardiovascular eventsNet adverse clinical eventsAcute Myocardial Infarction trialObstructive coronary artery diseaseLeft ventricular ejection fractionLower body mass indexBaseline coronary angiogramAdverse cardiovascular eventsCoronary artery bypassMyocardial Infarction trialNormal coronary arteriesOutcomes of patientsAdverse clinical eventsPrognosis of patientsVentricular ejection fractionBody mass indexQuantitative coronary angiographyRate of death
2011
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 2011, 7: 905-16. PMID: 22157475, DOI: 10.4244/eijv7i8a144.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingMyocardial infarctionTF approachMajor adverse cardiovascular eventsNet adverse clinical eventsAdverse cardiovascular eventsEvent-free survivalAdverse clinical eventsPercutaneous coronary interventionImproved clinical outcomesAcute myocardial infarctionOne-year ratesRate of deathPaucity of dataComposite deathHORIZONS-AMICardiovascular eventsPrimary angioplastyAnticoagulation regimensCoronary interventionImpact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial
Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal 2011, 161: 391-396. PMID: 21315224, DOI: 10.1016/j.ahj.2010.11.001.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionPrimary percutaneous coronary interventionBaseline thrombocytopeniaMajor cardiac eventsPercutaneous coronary interventionMyocardial infarctionMajor bleedingPrimary angioplastyCardiac eventsCoronary interventionLate outcomesNet adverse clinical eventsAcute Myocardial Infarction trialHORIZONS-AMI trialMajor cardiovascular eventsMyocardial Infarction trialOutcomes of patientsAcute coronary syndromeAdverse clinical eventsEarly adverse eventsAcute myocardial infarctionHarmonizing OutcomesCardiovascular eventsCoronary syndromeAdverse events
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac eventsBivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implicationsThe GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial. JACC Cardiovascular Interventions 2009, 2: 205-214. PMID: 19463427, DOI: 10.1016/j.jcin.2008.12.011.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsMajor adverse cardiac event ratesAdverse cardiac event ratesSingle de novo lesionsMajor adverse clinical eventsStent late lumen lossEnd pointBinary angiographic restenosisCardiac event ratePrimary end pointSecondary end pointsDe novo lesionsRandomized multicenter trialAdverse clinical eventsStent late lossLate lumen lossNative coronary arteriesStent restenosis rateBare metal stentsAngiographic restenosisNovo lesionsCoronary angiographyMulticenter trialRestenosis rateLumen loss
2000
Randomized Trial of Contrast Media Utilization in High-Risk PTCA
Davidson C, Laskey W, Hermiller J, Harrison J, Matthai W, Vlietstra R, Brinker J, Kereiakes D, Muhlestein J, Lansky A, Popma J, Buchbinder M, Hirshfeld J. Randomized Trial of Contrast Media Utilization in High-Risk PTCA. Circulation 2000, 101: 2172-2177. PMID: 10801758, DOI: 10.1161/01.cir.101.18.2172.Peer-Reviewed Original ResearchConceptsMajor adverse clinical eventsHospital major adverse clinical eventsPrimary end pointClinical eventsNonionic dimer iodixanolDimer iodixanolEnd pointLow-osmolar contrast agentsHigh-risk PTCAHospital clinical eventsThrombus-related eventsTotal clinical eventsDouble-blind trialAcute coronary syndromeHigh-risk patientsProspective multicenter trialAdverse clinical eventsCoronary artery interventionPTCA outcomeAngiographic successCoronary syndromeNovo lesionsArtery interventionMulticenter trialRandomized trialsLong-term clinical events following creatine kinase–myocardial band isoenzyme elevation after successful coronary stenting
Saucedo J, Mehran R, Dangas G, Hong M, Lansky A, Kent K, Satler L, Pichard A, Stone G, Leon M. Long-term clinical events following creatine kinase–myocardial band isoenzyme elevation after successful coronary stenting. Journal Of The American College Of Cardiology 2000, 35: 1134-1141. PMID: 10758952, DOI: 10.1016/s0735-1097(00)00513-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAngioplasty, Balloon, CoronaryBiomarkersCoronary DiseaseCreatine KinaseDisease-Free SurvivalFemaleHumansIncidenceLogistic ModelsMaleMiddle AgedPredictive Value of TestsPrognosisProspective StudiesPulmonary EdemaRadiographyRecurrenceRisk FactorsSeverity of Illness IndexStentsTreatment OutcomeConceptsCK-MB elevationCreatine kinase-myocardial band isoenzyme (CK-MB) elevationMajor adverse clinical eventsCK-MB riseAdverse clinical eventsCoronary stentingLate mortalityClinical eventsGroup 1Group 3Group 2Long-term clinical importanceLong-term clinical eventsHospital recurrent ischemiaLate clinical outcomesCardiac enzyme elevationEvent-free survivalClinical end pointsHigher late mortalityPercutaneous coronary interventionPercutaneous coronary revascularizationCK-MB levelsNative coronary arteriesSuccessful coronary stentingSuccessful stent implantationRelation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report)
Saucedo J, Popma J, Kennard E, Talley J, Lansky A, Leon M, Baim D, Investigators F. Relation of coronary artery size to one-year clinical events after new device angioplasty of native coronary arteries (a New Approach to Coronary Intervention [NACI] Registry report). The American Journal Of Cardiology 2000, 85: 166-171. PMID: 10955371, DOI: 10.1016/s0002-9149(99)00649-9.Peer-Reviewed Original ResearchConceptsReference vessel diameterNew device angioplastyNative coronary arteriesMinimal lumen diameterClinical eventsAngiographic outcomesCoronary arteryFinal minimal lumen diameterFinal percent diameter stenosisMajor adverse clinical eventsOne-year clinical eventsSmaller reference vessel diameterBaseline lesion characteristicsRisk of TLRCombined end pointAdverse clinical eventsCoronary artery diseaseCoronary Intervention RegistryEarly clinical eventsIncidence of deathSmall vesselsCoronary artery sizePercent diameter stenosisLesion revascularizationMultivessel disease